3D bioprinting: From lab to life-saving

Let’s dive into the amazing world of 3D bioprinting, which has applications in drug discovery, wound healing, surgical planning, and organ transplantation.

I am especially intrigued by the 3D bioprinting of organs. My PhD was on transplantation and hepatitis C reinfection, and I ran a small clinical trial of 20 patients, all of whom had undergone a liver transplant.

The indications for needing new livers were varied. Some due to chronic alcohol use, some due to congenital metabolic liver diseases like alpha-1 antitrypsin deficiency or Wilson disease, and a few patients with paracetamol overdoses. The one thing they all had in common was needing to wait for a suitable donor, often taking several months.

While experimental xenotransplantation has made progress, survival times remain short, with significant challenges like thrombocytopenia and immune rejection limiting its success.

But what if we could just print new organs?

For decades, organ transplantation has been limited by donor shortages and tissue compatibility. But 3D bioprinting is changing the equation.

🫁 3D bioprinting is the process of using bioinks - composed of living cells, biomaterials, and growth factors - to create three-dimensional, tissue-like structures through a layer-by-layer additive manufacturing technique for applications in medicine, tissue engineering, and research

A revolution in the making

Scientists and bioengineers are now printing human tissues - and eventually, whole organs - using specialized “bioinks” made of living cells. What once sounded like science fiction is fast becoming medical reality.

A team at Harvard’s Wyss Institute recently printed kidney tissue capable of filtering waste. United Therapeutics and 3D Systems have created intricate lung scaffolds. At the Wake Forest Institute for Regenerative Medicine, researchers are printing skin grafts for burn victims and trauma patients.

These aren’t just lab demonstrations - they represent real-world clinical progress. Bioprinted cartilage and corneas are already in use. Heart and liver patches are entering preclinical trials.

A 3-D bioprinter extruding a “bioink” with suspended human cells to create a trilayer tissue structure. Image: Wake Forest Institute for Regenerative Medicine.

The field is advancing at a breathtaking pace, and the next decade promises to be transformative.

The road ahead: What will the next decade bring?

In the next 3 years

Hospitals will begin incorporating 3D-printed cartilage, corneas, and skin into reconstructive procedures. Researchers will refine miniaturized organs-on-a-chip, enabling pharmaceutical companies to test drugs on lab-grown human tissues rather than animals. Meanwhile, the FDA will accelerate approvals for bio-printed tissue implants, opening the door for wider clinical applications.

Expect to see:

• Expansion of bioprinted skin for burn treatments.

• Clinical trials for 3D-printed heart patches.

• Increasing integration of AI-driven bioprinting processes to refine tissue structures.

Five years from now

Imagine a world where bioprinted liver tissue is used to restore function in patients with chronic disease, where bio-inks containing immune-compatible cells make organ rejection a relic of the past. Advances in vascularization techniques will allow printed organs to develop functioning blood vessels, solving one of the biggest challenges in the field. Hospitals could see the first human trials of bioprinted heart tissue patches, helping repair damage from heart attacks.

Other breakthroughs expected in this timeframe include:

• Bioprinted kidney prototypes capable of partial filtration.

• Pancreatic tissue for diabetes treatments.

• Functional nerve grafts for spinal injuries.

A decade into the future

By the early 2030s, fully functional 3D-printed kidneys and pancreases may enter clinical trials for transplantation. The notion of relying on donor organs could feel archaic, as custom-printed, patient-specific organs become the gold standard. And with AI-driven bioprinters optimizing designs in real-time, we may see personalized organs printed on demand, matched perfectly to a patient’s genetics and physiology.

Furthermore, medical professionals may begin relying on automated organ printing labs that operate within hospitals, significantly cutting down transplant wait times.

Companies leading the charge

Cellink: Engineering the future of regenerative medicine

In a sleek biotech lab, Cellink is developing cutting-edge bioprinting technology that enables the creation of complex human tissues. Their latest success? Printing functional liver tissue that closely mimics natural organ behavior - a major leap toward full-scale transplantable organs.

Prellis Biologics: Cracking the code of vascularization

One of the biggest hurdles in bioprinting has been creating intricate blood vessel networks. Prellis Biologics is leading the charge, developing microvascularized tissues capable of delivering oxygen and nutrients to growing organs. Its technology is 1,000 times faster than conventional bioprinters, enabling the creation of vascularized tissue structures in hours rather than weeks.

United Therapeutics: Printing the breath of life

Lung transplantation is among the most complex and high-risk procedures, but United Therapeutics is making extraordinary strides. Their bioprinted lung scaffolds, already tested in lab environments, maybe the stepping stone to the world’s first 3D-printed, fully functional human lungs.

Beyond the science: The ethical and logistical challenges

As with any revolutionary technology, bioprinted organs come with ethical and logistical dilemmas. Who will have access to these life-saving innovations? Will printed organs be limited to those who can afford them? How will regulators ensure safety and longevity?

Moreover, there’s the fundamental question of ownership. If a company prints an organ from a patient’s own cells, does the patient own it outright, or does intellectual property law come into play?

Beyond the ethics, practical challenges remain. Scaling production to meet global demand will be no easy feat, and ensuring that printed organs function as effectively as naturally developed ones over a patient’s lifetime will require years of rigorous testing.

• Regulatory hurdles remain a significant barrier.

• Affordability and accessibility must be addressed to prevent healthcare disparities.

• Long-term performance data will be critical for widespread adoption.

What this means for healthcare leaders

For hospitals and surgeons, the integration of bioprinting into medical practice is inevitable - it’s just a question of how soon. Investors should take note: bioprinting is set to become a multi-billion-dollar industry over the next decade, with opportunities spanning biotech, pharmaceuticals, and personalized medicine.

And for policymakers, the race is on to develop regulatory frameworks that balance innovation with safety. Laws and guidelines must evolve as rapidly as the science itself to ensure that this life-changing technology reaches those who need it most.

The future is printing

Three years from now, 3D-printed tissues will be commonplace in hospitals. In five years, bioprinted liver and heart tissue will enter mainstream drug testing. And within a decade, fully transplantable, patient-specific organs may become reality.

The question is no longer if bioprinting will change medicine - it’s when. And when it does, it will reshape the future of healthcare as we know it.

***

📫 If you enjoyed reading this article, please consider subscribing to the Healthy Innovations newsletter, where I distil the most impactful advances across medicine, biotechnology, and digital health into a 5-minute briefing that helps you see the incredible future of healthcare taking shape.